Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Short term Debt (2023 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Short term Debt for 3 consecutive years, with $12.0 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Short term Debt rose 1071.3% year-over-year to $12.0 million, compared with a TTM value of $12.0 million through Mar 2025, up 1071.3%, and an annual FY2024 reading of $15.1 million, changed N/A over the prior year.
  • Short term Debt was $12.0 million for Q1 2025 at Xeris Biopharma Holdings, down from $15.1 million in the prior quarter.
  • Across five years, Short term Debt topped out at $17.5 million in Q3 2023 and bottomed at $420000.0 in Q2 2024.
  • Average Short term Debt over 3 years is $11.6 million, with a median of $15.0 million recorded in 2023.
  • The sharpest move saw Short term Debt plummeted 97.48% in 2024, then surged 1071.3% in 2025.
  • Year by year, Short term Debt stood at $17.5 million in 2023, then dropped by 13.79% to $15.1 million in 2024, then decreased by 20.81% to $12.0 million in 2025.
  • Business Quant data shows Short term Debt for XERS at $12.0 million in Q1 2025, $15.1 million in Q4 2024, and $15.1 million in Q3 2024.